- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting RTK Signaling Pathways in Cancer
Authors
Keywords
-
Journal
Cancers
Volume 7, Issue 3, Pages 1758-1784
Publisher
MDPI AG
Online
2015-09-03
DOI
10.3390/cancers7030860
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The MAPK ERK5, but not ERK1/2, inhibits the progression of monocytic phenotype to the functioning macrophage
- (2015) Xuening Wang et al. EXPERIMENTAL CELL RESEARCH
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance
- (2015) Kimmo J. Hatanpaa et al. NEOPLASIA
- Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer
- (2014) Ekta Agarwal et al. BMC CANCER
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
- (2014) Timothy J Price et al. LANCET ONCOLOGY
- A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours
- (2013) D W Bowles et al. BRITISH JOURNAL OF CANCER
- Molecular and cellular pathogenesis of melanoma initiation and progression
- (2013) Tarik Regad CELLULAR AND MOLECULAR LIFE SCIENCES
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
- (2013) G. I. Shapiro et al. CLINICAL CANCER RESEARCH
- Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
- (2013) R. M. Campbell et al. MOLECULAR CANCER THERAPEUTICS
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma
- (2013) V Munugalavadla et al. ONCOGENE
- Signal Transduction by Vascular Endothelial Growth Factor Receptors
- (2013) S. Koch et al. Cold Spring Harbor Perspectives in Medicine
- Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates
- (2012) Ted Underiner et al. Anti-Cancer Agents in Medicinal Chemistry
- ERK5 and its role in tumour development: Figure 1
- (2012) Pamela A. Lochhead et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Exploring the function of the JNK (c-Jun N-terminal kinase) signalling pathway in physiological and pathological processes to design novel therapeutic strategies
- (2012) Clare Davies et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Mechanisms of FGFR-mediated carcinogenesis
- (2012) Imran Ahmad et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
- (2012) Nancy U. Lin et al. BREAST CANCER RESEARCH AND TREATMENT
- mTOR inhibitors in cancer therapy
- (2012) Yekaterina Y. Zaytseva et al. CANCER LETTERS
- Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity
- (2012) Paul G Richardson et al. Expert Opinion on Drug Metabolism & Toxicology
- Therapeutic targeting of c-KIT in cancer
- (2012) Leonie K Ashman et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy
- (2012) Libero Santarpia et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Stem Cell Factor Receptor/c-Kit: From Basic Science to Clinical Implications
- (2012) Johan Lennartsson et al. PHYSIOLOGICAL REVIEWS
- PI3K-PKB/Akt Pathway
- (2012) B. A. Hemmings et al. Cold Spring Harbor Perspectives in Biology
- MAP Kinase Pathways
- (2012) D. K. Morrison Cold Spring Harbor Perspectives in Biology
- Blocking the mTOR pathway: a drug discovery perspective
- (2011) Carlos Garcia-Echeverria BIOCHEMICAL SOCIETY TRANSACTIONS
- Receptor Tyrosine Kinases and Targeted Cancer Therapeutics
- (2011) Kenji Takeuchi et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
- (2011) J. Hoellenriegel et al. BLOOD
- Mutant BRAF Melanomas—Dependence and Resistance
- (2011) Poulikos I. Poulikakos et al. CANCER CELL
- Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
- (2011) C. Cauchi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
- (2011) Seth A. Wander et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Breast Cancer-Derived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET Knockdown
- (2011) S. Previdi et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
- (2011) S. V. Bhagwat et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms and functions of p38 MAPK signalling
- (2010) Ana Cuadrado et al. BIOCHEMICAL JOURNAL
- New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases
- (2010) F. Toffalini et al. BLOOD
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung
- (2010) Donatella Malanga et al. CELL CYCLE
- 8p11 myeloproliferative syndrome: a review
- (2010) Courtney C. Jackson et al. HUMAN PATHOLOGY
- Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase
- (2009) M. Ren et al. BLOOD
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
- (2009) J. P. Eder et al. CLINICAL CANCER RESEARCH
- Molecular determinants of tumor recurrence in the urinary bladder
- (2009) Liang Cheng et al. Future Oncology
- Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma
- (2009) Helena Nord et al. INTERNATIONAL JOURNAL OF CANCER
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors
- (2009) K.A. Hahn et al. JOURNAL OF VETERINARY INTERNAL MEDICINE
- FGFR3 mutations in prostate cancer: association with low-grade tumors
- (2009) Silvia Hernández et al. MODERN PATHOLOGY
- SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo
- (2009) S. G. Buchanan et al. MOLECULAR CANCER THERAPEUTICS
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
- (2009) A F Gazdar ONCOGENE
- Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip
- (2009) Annie Chou et al. ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS
- De-regulated FGF receptors as therapeutic targets in cancer
- (2009) Victoria Knights et al. PHARMACOLOGY & THERAPEUTICS
- Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias
- (2008) M S Kim et al. BRITISH JOURNAL OF CANCER
- A novel AKT3 mutation in melanoma tumours and cell lines
- (2008) M A Davies et al. BRITISH JOURNAL OF CANCER
- FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival
- (2008) K. Kunii et al. CANCER RESEARCH
- Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
- (2008) N. Rhodes et al. CANCER RESEARCH
- Characterization of the Recurrent 8p11-12 Amplicon Identifies PPAPDC1B, a Phosphatase Protein, as a New Therapeutic Target in Breast Cancer
- (2008) I. Bernard-Pierrot et al. CANCER RESEARCH
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
- (2008) H. Huynh et al. CLINICAL CANCER RESEARCH
- A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
- (2008) D. Sarker et al. CLINICAL CANCER RESEARCH
- Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation
- (2008) Lijian Hui et al. JOURNAL OF CLINICAL INVESTIGATION
- Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer
- (2008) Qingshan Chang et al. JOURNAL OF HEPATOLOGY
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
- Drug development of MET inhibitors: targeting oncogene addiction and expedience
- (2008) Paolo M. Comoglio et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting EGFR in Colorectal Cancer
- (2008) Wells A. Messersmith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
- Mitogen-Activated Protein (MAP) Kinase/MAP Kinase Phosphatase Regulation: Roles in Cell Growth, Death, and Cancer
- (2008) T. Boutros et al. PHARMACOLOGICAL REVIEWS
- Drug-sensitive FGFR2 mutations in endometrial carcinoma
- (2008) A. Dutt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Allele-Specific Up-Regulation of FGFR2 Increases Susceptibility to Breast Cancer
- (2008) Kerstin B Meyer et al. PLOS BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More